Skip to content
Companies

Vivace Therapeutics

Hippo pathway drugs for mesothelioma and solid tumors

Raised to date

$17.5M

of $35M offered across 1 Form D filing

Still open
$17.5M
Investors
5
Last filed
Mar 12, 2025

About

Vivace Therapeutics, Inc. is a pioneering biotechnology firm focused on creating innovative cancer treatments that specifically target the Hippo-YAP signaling pathway. The company aims to deliver solutions for cancer patients with limited options, particularly those suffering from challenging malignancies driven by pathway dysregulation.

Vivace stands out by focusing on the Hippo pathway, which is often overlooked in cancer research, and has developed VT3989—a promising small molecule drug that has shown early success in clinical trials.

Funding

  • EquityFiled Mar 12, 2025Form D
    $17.5M/ $35M

Product

VT3989

Cancer Treatment

VT3989 is an innovative small molecule drug designed to inhibit TEAD autopalmitoylation within the Hippo signaling pathway. This mechanism aims to counteract the effects of pathway dysregulation that can lead to tumorigenesis, particularly in cancers like mesothelioma and other solid tumors characterized by NF2 mutations.

  • Targets the Hippo-YAP signaling pathway
  • Inhibits TEAD autopalmitoylation
  • Specifically developed for cancers with NF2 mutations

Built for

Cancer patients, particularly those with mesothelioma and solid tumors

People on file